RNV 1002
Alternative Names: RNV-1002Latest Information Update: 26 Sep 2022
Price :
$50 *
At a glance
- Originator REDNVIA
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Aortic valve stenosis
Most Recent Events
- 20 Sep 2022 Early research in Aortic valve stenosis in South Korea, prior to September 2022 (REDNVIA pipeline, September 2022)